keyword
MENU ▼
Read by QxMD icon Read
search

Nonmotor parkinson's disease

keyword
https://www.readbyqxmd.com/read/28643887/personality-dopamine-and-parkinson-s-disease-insights-from-subthalamic-stimulation
#1
Eugénie Lhommée, François Boyer, Maxime Wack, Pierre Pélissier, Hélène Klinger, Emmanuelle Schmitt, Amélie Bichon, Valérie Fraix, Stéphan Chabardès, Patrick Mertens, Anna Castrioto, Andrea Kistner, Emmanuel Broussolle, Stéphane Thobois, Paul Krack
BACKGROUND: Subthalamic stimulation improves the motor and neuropsychiatric symptoms of Parkinson's disease. However, the impact of this treatment on impulse control and personality is the subject of heavy debate. The objective of this study was to investigate personality changes after subthalamic stimulation. METHODS: Using Cloninger's biosocial model, we assessed personality in 73 Parkinson's disease patients before and 12 months after subthalamic stimulation accompanied by a drastic reduction in dopaminergic medication...
June 23, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28638717/validation-of-the-parkinson-fatigue-scale-in-chinese-parkinson-s-disease-patients
#2
Rao Fu, Shi-Shuang Cui, Juan-Juan Du, Pei Huang, Ya-Chao He, Chao Gao, Xiao-Guang Luo, Sheng-Di Chen
OBJECTIVE: Fatigue is a common nonmotor symptom in Parkinson's disease (PD); however, the Parkinson's disease fatigue scale (PFS), which is designed to measure fatigue in PD, has not been validated in China. The aim of this study was to determine the validity and reliability of the Chinese version of the PFS in PD patients. METHODS: A total of 115 PD patients were evaluated at baseline and after 7 days. Assessments included the PFS, the Fatigue Severity Scale (FSS), and scales assessing motor, cognition, depression, and anxiety...
June 2017: Brain and Behavior
https://www.readbyqxmd.com/read/28637374/facial-emotion-recognition-in-parkinson-s-disease-association-with-age-and-olfaction
#3
S Kalampokini, E Lyros, M Luley, J Schöpe, J Spiegel, J Bürmann, U Dillmann, K Fassbender, M M Unger
OBJECTIVE: The ability to recognize facial emotion expressions has been reported to be impaired in Parkinson's disease (PD), yet previous studies showed inconsistent findings. The aim of this study was to further investigate facial emotion recognition (FER) in PD patients and its association with demographic and clinical parameters (including motor and nonmotor symptoms). METHOD: Thirty-four nondemented PD patients and 24 age- and sex-matched healthy controls (HC) underwent clinical neurological and neuropsychological assessment, standardized olfactory testing with Sniffin' Sticks, and the Ekman 60 Faces Emotion Recognition Test...
June 21, 2017: Journal of Clinical and Experimental Neuropsychology
https://www.readbyqxmd.com/read/28630780/a-randomized-controlled-trial-of-chinese-medicine-on-nonmotor-symptoms-in-parkinson-s-disease
#4
Ka-Kit Chua, Adrian Wong, Kam-Wa Chan, Yin-Kei Lau, Zhao-Xiang Bian, Jia-Hong Lu, Liang-Feng Liu, Lei-Lei Chen, Ka-Ho Chan, Kim-Pong Tse, Anne Chan, Ju-Xian Song, Justin Wu, Li-Xing Zhu, Vincent Mok, Min Li
Nonmotor symptoms (NMS) of Parkinson's disease (PD) have devastating impacts on both patients and their caregivers. Jiawei-Liujunzi Tang (JLT) has been used to treat some NMS of PD based on the Chinese medicine theory since Qing dynasty. Here we report a double-blind, randomized, placebo-controlled, add-on clinical trial aiming at evaluating the efficacy and safety of the JLT in treating NMS in PD patients. We randomly assigned 111 patients with idiopathic PD to receive either JLT or placebo for 32 weeks. Outcome measures were baseline to week 32 changes in Movement Disorder Society-Sponsored Revision of Unified PD Rating Scale (MDS-UPDRS) Parts I-IV and in NMS assessment scale for PD (NMSS)...
2017: Parkinson's Disease
https://www.readbyqxmd.com/read/28607801/quantitative-analysis-of-motor-status-in-parkinson-s-disease-using-wearable-devices-from-methodological-considerations-to-problems-in-clinical-applications
#5
REVIEW
Masahiko Suzuki, Hiroshi Mitoma, Mitsuru Yoneyama
Long-term and objective monitoring is necessary for full assessment of the condition of patients with Parkinson's disease (PD). Recent advances in biotechnology have seen the development of various types of wearable (body-worn) sensor systems. By using accelerometers and gyroscopes, these devices can quantify motor abnormalities, including decreased activity and gait disturbances, as well as nonmotor signs, such as sleep disturbances and autonomic dysfunctions in PD. This review discusses methodological problems inherent in wearable devices...
2017: Parkinson's Disease
https://www.readbyqxmd.com/read/28589163/a-novel-design-of-a-phase-iii-trial-of-isradipine-in-early-parkinson-disease-steady-pd-iii
#6
Kevin M Biglan, David Oakes, Anthony E Lang, Robert A Hauser, Karen Hodgeman, Brittany Greco, Jillian Lowell, Rebecca Rockhill, Ira Shoulson, Charles Venuto, Diony Young, Tanya Simuni
OBJECTIVE: To describe the rationale for a novel study design and baseline characteristics of a disease-modifying trial of isradipine 10 mg daily in early Parkinson disease (PD). METHODS: STEADY-PDIII is a 36-month, Phase 3, parallel group, placebo-controlled study of the efficacy of isradipine 10 mg daily in 336 participants with early PD as measured by the change in the Unified Parkinson Disease Rating Scale (UPDRS) Part I-III score in the practically defined ON state...
June 2017: Annals of Clinical and Translational Neurology
https://www.readbyqxmd.com/read/28579482/precuneus-degeneration-and-isolated-apathy-in-patients-with-parkinson-s-disease
#7
Jung Hwan Shin, Seong A Shin, Jee-Young Lee, Hyunwoo Nam, Jae-Sung Lim, Yu Kyeong Kim
INTRODUCTION: To investigate isolated apathy in a set of consecutively enrolled Parkinson's disease (PD) patients without dementia, depression, and significant motor response fluctuations, by conducting neuropsychological and neuroimaging analyses. METHODS: One hundred twenty-four patients were eligible for inclusion in this study. Clinical information and data were collected from a predefined neuropsychological test battery, including the mini-mental status examination, apathy scale, geriatric depression scale, digit span test, Boston naming test, Seoul verbal learning test, controlled oral word association test, go-no-go test, and the Rey figure copy test...
June 1, 2017: Neuroscience Letters
https://www.readbyqxmd.com/read/28577987/alcar-promote-adult-hippocampal-neurogenesis-by-regulating-cell-survival-and-cell-death-related-signals-in-rat-model-of-parkinson-s-disease-like-phenotypes
#8
Sonu Singh, Akanksha Mishra, Sandeep Kumar Mishra, Shubha Shukla
Parkinson's disease (PD) is characterized by the degeneration of dopaminergic neurons in the nigrostriatal pathway that leading to progressive motor and nonmotor symptoms. The formation of newborn neurons in the adult hippocampus is affected by many factors such as anxiety, depression and impairment in learning and memory that are commonly observed nonmotor symptoms in PD, indicating the role of adult neurogenesis in PD pathophysiology. Acetyl-l-carnitine (ALCAR), regulate mitochondrial metabolism and has been reported to improve cognitive functions in different neurodegenerative disorders through an unknown mechanism...
May 31, 2017: Neurochemistry International
https://www.readbyqxmd.com/read/28574926/hyposmia-symptoms-of-rapid-eye-movement-sleep-behavior-disorder-and-parkinsonian-motor-signs-suggest-prodromal-neurodegeneration-in-22q11-deletion-syndrome
#9
Ellen Buckley, Azeem Siddique, Alisdair McNeill
The 22q11 deletion syndrome (22q11DS) is one of the most common genomic disorders in humans. There is an increased risk of Parkinson's disease (PD) in individuals with 22q11DS. The characteristic motor features of PD begin when more than 50% of dopaminergic neurons in the substantia nigra have degenerated. Before this, there is a prodromal period, of up to 20 years, in which nonmotor features such as hyposmia, autonomic dysfunction, rapid eye movement sleep behavior disorder, and subtle motor dysfunction can occur...
June 1, 2017: Neuroreport
https://www.readbyqxmd.com/read/28562526/efficacy-of-antidepressive-medication-for-depression-in-parkinson-disease-a-network-meta-analysis
#10
Chuanjun Zhuo, Rong Xue, Lanlan Luo, Feng Ji, Hongjun Tian, Hongru Qu, Xiaodong Lin, Ronghuan Jiang, Ran Tao
BACKGROUND: Parkinson disease (PD) was considered as the 2nd most prevalent neurodegenerative disorder after Alzheimer disease, while depression is a prevailing nonmotor symptom of PD. Typically used antidepression medication includes tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake inhibitors (SNRI), monoamine-oxidase inhibitors (MAOI), and dopamine agonists (DA). Our study aimed at evaluating the efficacy of antidepressive medications for depression of PD...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28554422/advances-in-the-clinical-differential-diagnosis-of-parkinson-s-disease
#11
Sebastian R Schreglmann, Kailash P Bhatia, Maria Stamelou
The differential diagnosis of Parkinson's disease has widened considerably in recent years. This chapter aims to summarize the current knowledge on the clinical differential diagnoses of sporadic Parkinson's disease. As the number of monogenic familial Parkinson's disease variants and risk factors is growing, so is the number of appreciated etiologies of atypical parkinsonian and other pallidopyramidal syndromes. This work aims at summarizing the current knowledge on both motor and nonmotor neurological signs and symptoms that aid the clinical diagnosis of Parkinson's disease and its differential diagnoses...
2017: International Review of Neurobiology
https://www.readbyqxmd.com/read/28554421/the-new-diagnostic-criteria-for-parkinson-s-disease
#12
Ronald B Postuma, Daniela Berg
This chapter summarizes the advances in diagnosis of Parkinson's disease (PD) that were encapsulated in new International Parkinson Disease and Movement Disorders Society diagnostic criteria for PD. Numerous changes in our understanding of PD have occurred, including our understanding of the nonmotor profile of disease, the recognition of PD as a synucleinopathy, identification of genetic causes, novel hypotheses about spread of disease, etc. These have been reflected in a new definition of PD, which includes a clinicogenetic subtype of PD, removes dementia with Lewy Bodies as an exclusion criterion against PD, and recognizes multiple stages of early disease...
2017: International Review of Neurobiology
https://www.readbyqxmd.com/read/28554420/multidisciplinary-care-in-parkinson-s-disease
#13
Mubasher A Qamar, Grace Harington, Sally Trump, Julia Johnson, Fiona Roberts, Emily Frost
Parkinson's disease (PD) is now known to be a multisystemic and multipeptide neurodegenerative disorder, whereby patients have an array of symptoms both motor and nonmotor. Nonmotor features of PD have been shown to arise almost 15-20 years prior to motor symptoms and, as such, are also a key determinant to the quality of life of a patient. Therefore, there is increasing evidence that a PD patient's management must encompass a multidisciplinary approach to effectively manage and treat the patient's PD and also their individual symptoms...
2017: International Review of Neurobiology
https://www.readbyqxmd.com/read/28554418/device-aided-treatment-strategies-in-advanced-parkinson-s-disease
#14
Jonathan Timpka, Bianca Nitu, Veronika Datieva, Per Odin, Angelo Antonini
With peroral levodopa treatment, a majority of patients develop motor fluctuations and dyskinesia already within a few years of therapy. Device-aided Parkinson (PD) therapies refer to deep brain stimulation (DBS), levodopa-carbidopa intestinal gel infusion (LCIG), and subcutaneous infusion of the dopamine agonist apomorphine and represent effective strategies counteracting motor fluctuations and dyskinesia. These three therapy options seem to be similarly effective in reducing "time with PD symptoms (off time)" by at least 60%-65%...
2017: International Review of Neurobiology
https://www.readbyqxmd.com/read/28554417/new-symptomatic-treatments-for-the-management-of-motor-and-nonmotor-symptoms-of-parkinson-s-disease
#15
Raquel N Taddei, Federica Spinnato, Peter Jenner
Motor symptoms are core features of Parkinson's disease, while nonmotor symptoms are present from the prodromal stage. Management strategies for the motor symptoms of Parkinson's disease have been widely researched and there have been many advances. Therapy has evolved from oral therapy to once a day to nonoral strategies, both for rescue and for infusion therapy. Treatment for nonmotor symptoms, however, has remained a key unmet need, although of late evidence base for management of some nonmotor symptoms such as pain, dementia, aspects of sleep dysfunction, and constipation has emerged...
2017: International Review of Neurobiology
https://www.readbyqxmd.com/read/28554416/treatment-of-older-parkinson-s-disease
#16
Abhishek Lenka, Chandrasekharapillai Padmakumar, Pramod K Pal
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. The prevalence of PD increases with age. The spectrum of clinical features, the rate of progression of the disease, the burden of nonmotor symptoms, and the response to medications are different in older patients with PD from the relatively younger patients. Management of symptoms of PD in older patients is challenging because of possible existence of several age-related systemic illness. While dealing with older patients, it is crucial not to attribute all the physical symptoms to PD...
2017: International Review of Neurobiology
https://www.readbyqxmd.com/read/28554415/treatment-of-nonmotor-symptoms-in-parkinson-s-disease
#17
Anna Sauerbier, Ilaria Cova, Miguel Rosa-Grilo, Raquel N Taddei, Laurie K Mischley, K Ray Chaudhuri
Nonmotor symptoms (NMS) are integral to Parkinson's disease (PD) and the management can often be challenging. In spite of the growing evidence that NMS have a key impact on the quality of life of patients and caregivers, most clinical trials still focus on motor symptoms as primary outcomes. As a consequence strong evidence-based treatment recommendations for NMS occurring in PD are spare. In this chapter, the current data addressing the treatment of major NMS such as sleep, cognitive and autonomic dysfunction, and depression and anxiety are described...
2017: International Review of Neurobiology
https://www.readbyqxmd.com/read/28554413/the-nonmotor-features-of-parkinson-s-disease
#18
Nataliya Titova, Mubasher A Qamar, K Ray Chaudhuri
Nonmotor symptoms (NMS) of Parkinson's disease (PD) were recognized by the great James Parkinson himself who mentioned symptoms such as sleep dysfunction, delirium, dementia, and dysautonomia, in his seminal 1817 essay, "An Essay on the Shaking Palsy" (Parkinson, 1817). In spite of the key impact of PD NMS on quality of life, there was little holistic research and awareness till the validation and use of comprehensive tools such as the NMS questionnaire, scale, and the revised version of the unified PD rating scale...
2017: International Review of Neurobiology
https://www.readbyqxmd.com/read/28554411/cerebrospinal-fluid-biomarkers-of-cognitive-decline-in-parkinson-s-disease
#19
Iskandar Johar, Brit Mollenhauer, Dag Aarsland
Among the nonmotor symptoms in Parkinson's disease (PD), cognitive impairment is one of the most common and devastating. Over recent years, mild cognitive impairment (MCI) has become a recognized feature of PD (PD-MCI). The underlying mechanisms which influence onset, rate of decline, and conversion to dementia (PDD) are largely unknown. Adding to this uncertainty is the heterogeneity of cognitive domains affected. Currently there are no disease-modifying treatments that can slow or reverse this process. Identification of biomarkers that can predict rate and risk of cognitive decline is therefore an unmet need...
2017: International Review of Neurobiology
https://www.readbyqxmd.com/read/28554408/genetics-of-parkinson-s-disease-genotype-phenotype-correlations
#20
Christos Koros, Athina Simitsi, Leonidas Stefanis
Since the first discovery of a specific genetic defect in the SNCA gene, encoding for α-synuclein, as a causative factor for Parkinson's disease 20 years ago, a multitude of other genes have been linked to this disease in rare cases with Mendelian inheritance. Furthermore, the genetic contribution to the much more common sporadic disease has been demonstrated through case control association studies and, more recently, genome-wide association studies. Interestingly, some of the genes with Mendelian inheritance, such as SNCA, are also relevant to the sporadic disease, suggesting common pathogenetic mechanisms...
2017: International Review of Neurobiology
keyword
keyword
70016
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"